Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.
Around the Helix: Cell and Gene Therapy Company Updates – June 18, 2025
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP
In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.
Beam’s Base-Editing HSC Therapy BEAM-101 Raises HbF Levels in Patients With Sickle Cell Disease
Beam Therapeutics’ team provided insight on data the company presented at EHA's 2025 Congress.
ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD
In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.
Omotayo Fasan, MRCP, DTM&H, MBBS, on Evaluating CAR-T GLPG5101 in R/R NHL
The head of the clinical development program at Galapagos discussed the company's data presented at EHA's 2025 Congress.
CAR-T KITE-363's Safety Profile in R/R B-Cell Lymphoma
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine, discussed safety and efficacy data from a phase 1 trial for Kite's CD19/CD20-directed CAR-T.